Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.
Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators.
In the United States, where Black inequity has become a focus of diversity efforts, biopharma companies are working hard to recruit and retain individuals from these communities. In fact, the search for such employees and leaders has become so competitive that competition for diverse talent within the industry is now "fierce," as one executive told In Vivo.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Strong headwinds beset the medtech industry as 2022 draws to a close, including supply chain, fundraising and labor shortages. However, optimism prevailed among medtech industry leaders discussing EY’s annual Pulse of the Industry medical technology report and related topics at AdvaMed’s 2022 MedTech Conference.
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.
The eighth annual MedTech Forum from APACMed chose Patient Futures as its 2022 theme. New chairman John Collings described to In Vivo how the local industry is seeking to both protect data and build trust with patients.
Marinus Pharmaceuticals’ CEO spoke candidly to In Vivo about breathing new life into ultra-rare epilepsy disorder drug ganaxolone.
With over 300 members involved in all aspects of the life sciences, SwedenBIO's ongoing mission is to make the country’s sector as visible as possible while ensuring each member's interests are being met. The non-profit recently welcomed Frida Lawenius as its Director General and, in a Q&A, she told In Vivo that one of the most pressing challenges facing the sector is recruiting the talent needed to keep up with its growth.
Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.
Debbie Dumont, co-founder of Bioqube Ventures, and one of In Vivo’s Rising Leaders, talks about the company’s investment model, Europe’s translational challenges, and aligning passion and purpose to find ultimate fulfilment.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.